Notably, KCNJ11 and ABCC8 are targets for commonly prescribed blood glucose-lowering medications, highlighting their clinical relevance in T2D management and emphasizing the therapeutic potential of interventions targeting these pathways [59,60]. The gene discussed is ABCC8; the disease is type 2 diabetes mellitus.